表紙
市場調查報告書

血脂異常症:疾病分析,市場·預測分析

Dyslipidemia Disease Analysis and Market and Forecast Analysis 2024

出版商 Datamonitor Healthcare 商品編碼 858221
出版日期 內容資訊 英文 546 Pages
商品交期: 最快1-2個工作天內
價格
血脂異常症:疾病分析,市場·預測分析 Dyslipidemia Disease Analysis and Market and Forecast Analysis 2024
出版日期: 2018年06月07日內容資訊: 英文 546 Pages
簡介

本報告提供血脂異常症治療藥市場相關調查分析,提供市場預測,治療,流行病學,上市藥,開發平台藥物趨勢等相關的系統性資訊。

預測:血脂異常症

  • 概要
  • 最新預測更新
  • 市場動態
  • 預測與未來趨勢
  • 市場定義·手法
  • 一次調查手法
  • 參考文獻
  • 產品簡介:CRESTOR
  • 產品簡介:JUXTAPID
  • 產品簡介:KYNAMRO
  • 產品簡介:LIPITOR
  • 產品簡介:PRALUENT
  • 產品簡介:REPATHA
  • 產品簡介:ZETIA FRANCHISE
  • 產品簡介 (後期階段) :BEMPEDOIC ACID FRANCHISE
  • 產品簡介 (後期階段) :EVINACUMAB
  • 產品簡介 (後期階段) :INCLISIRAN
  • 產品簡介 (後期階段) :VOLANESORSEN

治療:血脂異常症

  • 概要
  • 摘要整理
  • 一次調查手法
  • 疾病定義·診斷
  • 患者區分
  • 處方趨勢
  • 未滿足需求

流行病學:高膽固醇症·血脂異常症

  • 概要
  • 疾病的背景
  • 調查手法
  • 預測
  • 補充分析:美國的血脂異常症
  • 參考文獻
  • 附錄

上市藥:血脂異常症

  • 概要
  • Statin
  • PCSK9抑制劑
  • fiburato
  • Niacin
  • Omega-3脂肪酸
  • 其他藥劑
  • 產品簡介:CRESTOR
  • 產品簡介:EPANOVA
  • 產品簡介:JUXTAPID
  • 產品簡介:KYNAMRO
  • 產品簡介:LIPITOR
  • 產品簡介:LOVAZA
  • 產品簡介:PRALUENT
  • 產品簡介:REPATHA
  • 產品簡介:VASCEPA
  • 產品簡介:ZETIA FRANCHISE

PCSK9抑制劑的價格·償付·存取(點閱)

  • 概要
  • 摘要整理
  • 保險者的考察
  • 美國的價格
  • 美國的償付
  • 日本
  • EU5個國家市場價格
  • 法國
  • 德國
  • 義大利
  • 西班牙
  • 英國
  • 調查手法

開發平台(管線):血脂異常症

  • 概要
  • 臨床開發平台概要
  • 最近中止的藥物
  • 其他開發平台(管線)資源
  • 產品簡介 (後期階段) :BEMPEDOIC ACID FRANCHISE
  • 產品簡介 (後期階段) :EVINACUMAB
  • 產品簡介 (後期階段) :INCLISIRAN
  • 產品簡介 (後期階段) :VOLANESORSEN
目錄
Product Code: DMKC4708

OVERVIEW

Dyslipidemia refers to any increase or decrease in lipid levels from defined normal parameters, with physicians particularly focusing on the treatment of elevated LDL-C due to the well-established link between excessively elevated LDL-C and atherosclerosis. As such, LDL-C is a major modifiable risk factor for cardiovascular disease, one of the world's leading causes of morbidity and mortality. Other lipid level deviations in dyslipidemia include low levels of HDL-C, elevated total cholesterol, and elevated triglycerides.

MARKET SNAPSHOT

  • Generic erosion of key legacy product sales will be offset by the growth of the branded PCSK9 inhibitor class.
  • Datamonitor Healthcare's primary research survey of 238 physicians sheds light on prescribing patterns in dyslipidemia.
  • Dyslipidemia is a serious public health concern, as prevalence is high and it is a strong risk factor for CVD and CAD.
  • Positive CVOT data combined with steep discounts will drive PCSK9 uptake.
  • Inclisiran is a promising pipeline medication and has the opportunity to provide cost-effective PCSK9 inhibition.
  • Payers impose strict access controls on PCSK9 inhibitors.

TABLE OF CONTENTS

FORECAST: DYSLIPIDEMIA (Published on 22 June 2018)

  • OVERVIEW
  • RECENT FORECAST UPDATES
  • MARKET DYNAMICS
  • FORECAST AND FUTURE TRENDS
  • MARKET DEFINITION AND METHODOLOGY
  • PRIMARY RESEARCH METHODOLOGY
  • BIBLIOGRAPHY
  • PRODUCT PROFILE: CRESTOR
  • PRODUCT PROFILE: JUXTAPID
  • PRODUCT PROFILE: KYNAMRO
  • PRODUCT PROFILE: LIPITOR
  • PRODUCT PROFILE: PRALUENT
  • PRODUCT PROFILE: REPATHA
  • PRODUCT PROFILE: ZETIA FRANCHISE
  • PRODUCT PROFILE (LATE STAGE): BEMPEDOIC ACID FRANCHISE
  • PRODUCT PROFILE (LATE STAGE): EVINACUMAB
  • PRODUCT PROFILE (LATE STAGE): INCLISIRAN
  • PRODUCT PROFILE (LATE STAGE): VOLANESORSEN

TREATMENT: DYSLIPIDEMIA (Published on 19 June 2017)

  • OVERVIEW
  • EXECUTIVE SUMMARY
  • PRIMARY RESEARCH METHODOLOGY
  • DISEASE DEFINITION AND DIAGNOSIS
  • PATIENT SEGMENTATION
  • PRESCRIBING TRENDS
  • UNMET NEEDS IN DYSLIPIDEMIA

EPIDEMIOLOGY: HYPERCHOLESTEROLEMIA AND DYSLIPIDEMIA (Published on 07 June 2018)

  • OVERVIEW
  • DISEASE BACKGROUND
  • METHODOLOGY
  • FORECAST
  • SUPPLEMENTARY ANALYSIS: DYSLIPIDEMIA IN THE US
  • BIBLIOGRAPHY
  • APPENDIX: ADDITIONAL SOURCES

MARKETED DRUGS: DYSLIPIDEMIA (Published on 22 June 2018)

  • OVERVIEW
  • STATINS
  • PCSK9 INHIBITORS
  • FIBRATES
  • NIACINS
  • OMEGA-3 FATTY ACIDS
  • OTHER DRUG CLASSES
  • PRODUCT PROFILE: CRESTOR
  • PRODUCT PROFILE: EPANOVA
  • PRODUCT PROFILE: JUXTAPID
  • PRODUCT PROFILE: KYNAMRO
  • PRODUCT PROFILE: LIPITOR
  • PRODUCT PROFILE: LOVAZA
  • PRODUCT PROFILE: PRALUENT
  • PRODUCT PROFILE: REPATHA
  • PRODUCT PROFILE: VASCEPA
  • PRODUCT PROFILE: ZETIA FRANCHISE

PCSK9 INHIBITORS PRICING, REIMBURSEMENT, AND ACCESS (Published on 21 December 2016)

  • OVERVIEW
  • EXECUTIVE SUMMARY
  • PAYER INSIGHTS
  • US PRICING
  • US REIMBURSEMENT
  • JAPAN
  • FIVE MAJOR EU MARKETS PRICING
  • FRANCE
  • GERMANY
  • ITALY
  • SPAIN
  • UK
  • METHODOLOGY

PIPELINE: DYSLIPIDEMIA (Published on 22 June 2018)

  • OVERVIEW
  • CLINICAL PIPELINE OVERVIEW
  • RECENTLY DISCONTINUED DRUGS
  • ADDITIONAL PHARMA INTELLIGENCE PIPELINE RESOURCES
  • PRODUCT PROFILE (LATE STAGE): BEMPEDOIC ACID FRANCHISE
  • PRODUCT PROFILE (LATE STAGE): EVINACUMAB
  • PRODUCT PROFILE (LATE STAGE): INCLISIRAN
  • PRODUCT PROFILE (LATE STAGE): VOLANESORSEN